{"id":"W4362619875","doi":"10.1097/hep.0000000000000395","title":"Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study","year":2023,"lang":"en","type":"article","venue":"Hepatology","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; McGill University Health Centre; University of Toronto; University Health Network","funders":"Cilag; Janssen Pharmaceuticals; Novartis Pharma; Genentech; Norgine; AOP Orphan; Eisai; Swedish Orphan Biovitrum; Novo Nordisk; Dr. Falk Pharma; Abbott Laboratories; National Institute for Health and Care Research; Pfizer; Moderna; Celgene; BioCryst; Loxo Oncology; Alnylam Pharmaceuticals; Cook Medical; Ipsen; Gilead Sciences; GlaxoSmithKline; U.S. Department of Justice; Allergan; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; NGM Biopharmaceuticals; Amgen; Kowa Company; Exelixis; Sanofi","keywords":"Medicine; Placebo; Randomized controlled trial; Biliary tract; Internal medicine; Gastroenterology; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000500877,0.000213359,0.001294484,0.0002299072,0.0001035848,0.000008820264,0.00007540351,0.0000927396,0.0001002518],"category_scores_gemma":[0.0002242822,0.0001477314,0.00009130391,0.0003013308,0.0001602222,0.00008157189,0.0001359256,0.0002171868,0.00005754174],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009741284,"about_ca_system_score_gemma":0.0001001146,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001812476,"about_ca_topic_score_gemma":0.00005727097,"domain_scores_codex":[0.9980783,0.00053679,0.00045085,0.0003681052,0.0002089962,0.0003569514],"domain_scores_gemma":[0.9986614,0.0006598373,0.0001144899,0.0003448766,0.00006818824,0.0001512119],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5051562,0.00189118,0.4906496,0.00004284646,0.0002994192,0.0001648868,0.0005318292,9.806863e-7,0.00001014465,0.000003361559,0.000295217,0.0009542683],"study_design_scores_gemma":[0.5711599,0.0009233314,0.4268314,0.00004074797,0.0003505116,0.000008140057,0.0001033096,0.0003670095,0.000006008821,0.000005811137,0.00009859445,0.0001052211],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933407,0.0004804554,0.000004249423,0.0001857662,0.00009012443,0.005080615,0.00002706759,0.0001030623,0.0006879846],"genre_scores_gemma":[0.9985083,0.0002414325,0.00002109155,0.0003055456,0.00002323726,0.0003481019,0.0002014664,0.00002548637,0.0003252944],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06600367,"threshold_uncertainty_score":0.6024311,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007566741783277263,"score_gpt":0.2672923729900228,"score_spread":0.2597256312067455,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}